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Introduction {#sec005}
============

Coronary artery disease (CAD) is the leading cause of death worldwide. Patients with CAD, especially acute coronary syndrome (ACS), are always at the high risk of recurrent cardiovascular events and death \[[@pone.0238288.ref001], [@pone.0238288.ref002]\]. Thus, there is a need to improve risk stratification in ACS using biomarkers beyond traditional cardiovascular risk factors to optimize treatment in clinical practice.

To date, several biomarkers such as natriuretic peptide, cardiac troponins and arginine vasopressin (AVP) have been studied as potential biomarkers for risk stratification in patients with ACS \[[@pone.0238288.ref003]--[@pone.0238288.ref006]\]. Among them, AVP, a nonapeptide produced in the hypothalamus, has been proved that it contributes to osmoregulation and cardiovascular homeostasis \[[@pone.0238288.ref007], [@pone.0238288.ref008]\]. However, AVP cannot be reliably measured in plasma due to its low stability. Copeptin, the C-terminal portion of provasopressin, is regarded as the ideal surrogate biomarker for AVP due to its favorable stability in blood \[[@pone.0238288.ref009], [@pone.0238288.ref010]\]. Thus, copeptin has been thought to be a potential biomarker for several acute illness, such as lower respiratory infection, acute pancreatitis, stroke and ACS \[[@pone.0238288.ref011]\].

Some studies have indicated that copeptin is a strong prognostic predictor on death in patients with ACS \[[@pone.0238288.ref012]--[@pone.0238288.ref017]\]. In contrast, no significant association of copeptin with the prognosis for survival after ACS was reported in other studies \[[@pone.0238288.ref018], [@pone.0238288.ref019]\]. The controversial findings might result from the differences in study design and limited sample size. Additionally, most of previous studies were conducted in single center, which might influence the generalizability of the results \[[@pone.0238288.ref013]--[@pone.0238288.ref016]\]. Accordingly, we aim to set out a systematic review and meta-analysis to evaluate the association between copeptin and mortality, and to quantify the value of copeptin in predicting mortality in patients with ACS.

Methods {#sec006}
=======

Literature search and selection {#sec007}
-------------------------------

We searched for relevant studies published in English up to December 2019 through the Pubmed/MEDLINE, EMBASE and Cochrane database with the following terms and their combinations: "copeptin", "C-terminal provasopressin", "coronary artery disease", "coronary heart disease", "angina", "myocardial infarction", "death" and "mortality".

We selected eligible studies from all the relevant literatures found in databases by orderly reviewing title, abstract and full text. The inclusion criteria were as follows: (1) studies focused on the value of copeptin in predicting mortality including both in-hospital and long-term mortality in patients with ACS or suspected ACS; (2) prospective cohort studies or randomized control trials (RCT); (3) studies with at least 1 month follow-up. Studies were excluded if: (1) we are not able to calculate sensitivity and specificity based on the data in the literature; (2) literatures are conference articles, editorial, letters, reviews or duplicated publications.

Data extraction and quality assessment {#sec008}
--------------------------------------

All the following information was separately extracted by two investigators: the first author\'s name, year of publication, study design, number of study centers, study outcome, duration of follow-up, number of patients enrolled, cut-off value of copeptin, number of true positive (TP), number of false positive (FP), number of false negative (FN) and number of true negative (TN). Discrepancies were resolved through discussion with the third investigator.

Quality assessment was conducted using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) \[[@pone.0238288.ref020]\]. The QUADAS-2 form is composed of four domains: (1) patient selection, (2) index test, (3) reference standard and (4) flow and timing. For each domain, the risk of bias and applicability concerns was analyzed and rated as "low", "high" and "unclear". Two investigators independently assessed the quality of the eligible studies and resolved disagreements by discussion.

Statistical analysis {#sec009}
--------------------

We calculated pooled sensitivity and specificity using a random-effects model \[[@pone.0238288.ref021]\]. Forest plots of each study and pooled estimates for sensitivity and specificity with 95% confidence intervals (95% CI) were used to visualize these results. We also presented a summary receiver operating characteristic curve (SROC) and calculated the area under the curve (AUC). The AUC close to 1 indicated a good performance for predicting mortality in ACS. Additionally, between-study heterogeneity of sensitivity and specificity was analyzed using the Cochrane's Q test and *I*^2^ index, and *P*\<0.1 or *I*^2^\>50% indicated statistically significant heterogeneity. Meta-regression analysis was conducted to identify potential between-study heterogeneity. Deek's test was used to assess the potential publication bias, and *P*\<0.05 indicated statistically significant publication bias. To assess the reliability of the pooled results, sensitivity analyses were conducted by removing one study each time to observe the influence of each study on the pooled estimates. All analyses were conducted using STATA 15.0 (STATA Corporation, College Station, Texas, USA).

Results {#sec010}
=======

Characteristics of the eligible studies {#sec011}
---------------------------------------

We identified 80 relevant studies by the literature search ([Fig 1](#pone.0238288.g001){ref-type="fig"}). After initial review of the title and abstract, 65 studies were excluded. Among them, 18 studies were reviews, 23 studies were not designed to evaluate the prognostic effect of copeptin in patients with ACS, and 24 studies didn't focus on patients with ACS. Among the 15 studies selected for full-text review, six studies didn't have sufficient data for the meta-analysis, one study was not prospective cohort study or RCT, one study didn't focus on mortality, one study didn't test baseline level of copeptin. Therefore, six studies were finally included in our meta-analysis \[[@pone.0238288.ref013]--[@pone.0238288.ref018]\]. Among the six included studies, five were prospective cohort studies, two were multi-center studies, and four studies had follow-up duration ≥6 months. A total of 2269 patients with ACS were studied. The characteristics of the final included studies were shown in [Table 1](#pone.0238288.t001){ref-type="table"}.

![Flowchart of study selection.\
ACS: acute coronary syndrome.](pone.0238288.g001){#pone.0238288.g001}

10.1371/journal.pone.0238288.t001

###### Characteristics of included studies.

![](pone.0238288.t001){#pone.0238288.t001g}

  Author                                        Year   Study design               Sample size   No. of study center   Duration of follow-up   Study outcome              Cut-off value of copeptin (pmol/L)
  --------------------------------------------- ------ -------------------------- ------------- --------------------- ----------------------- -------------------------- ------------------------------------
  Afzali, et al. \[[@pone.0238288.ref013]\]     2013   Prospective cohort study   227           1                     180 days                all-cause mortality        14
  Bahrmann, et al. \[[@pone.0238288.ref014]\]   2013   Prospective cohort study   306           1                     1 year                  cardiovascular mortality   14
  Morawiec, et al. \[[@pone.0238288.ref015]\]   2018   Prospective cohort study   151           1                     1 year                  cardiovascular mortality   17.4
  Narayan, et al. \[[@pone.0238288.ref016]\]    2011   Prospective cohort study   631           1                     180 days                all-cause mortality        7.9
  Sanchez, et al. \[[@pone.0238288.ref018]\]    2014   Prospective cohort study   377           15                    30 days                 all-cause mortality        25.9
  Vafaie, et al. \[[@pone.0238288.ref017]\]     2016   Randomized control trial   577           7                     90 days                 all-cause mortality        10

The result of quality assessment was shown in [Fig 2](#pone.0238288.g002){ref-type="fig"}. In general, all included studies in the meta-analysis showed good quality in methodology. In this study, we only included prospective cohort studies or RCTs. Therefore, all included studies had low risk of bias in patient selection. One study had unclear risk of bias in index test domain because the cut-off value of copeptin was not pre-specified \[[@pone.0238288.ref016]\]. One study was judged to be unclear risk of bias in flow and timing because only part of study patients were included in the final analysis \[[@pone.0238288.ref017]\]. However, none of the six eligible studies needed to be excluded from the meta-analysis due to methodological defects.

![Quality assessment of included studies using QUADAS-2.](pone.0238288.g002){#pone.0238288.g002}

Performance of copeptin in predicting mortality in patients with ACS {#sec012}
--------------------------------------------------------------------

The AUC of copeptin in predicting mortality in patients with ACS was 0.73 (95% CI: 0.69--0.77) ([Fig 3](#pone.0238288.g003){ref-type="fig"}). The pooled sensitivity and specificity of copeptin in predicting mortality in patients with ACS was 0.77 (95% CI: 0.59--0.89) and 0.60 (95% CI: 0.47--0.71), respectively ([Fig 4](#pone.0238288.g004){ref-type="fig"}). The positive likelihood ratio was 1.90 (95% CI: 1.60--2.30) and the negative likelihood ratio was 0.38 (95% CI: 0.23--0.64). The diagnostic odds ratio was 5.00 (95% CI: 3.00--9.00). The sensitivity analyses of diagnostic odds ratio showed that the combined estimate was 4.76 and the estimates varied between 3.57 and 5.39, which indicated that no single study could significantly influenced the combined estimates ([Table 2](#pone.0238288.t002){ref-type="table"}).

![Summary receiver operating characteristic curve of copeptin in predicting mortality in patients with acute coronary syndrome.](pone.0238288.g003){#pone.0238288.g003}

![Forest plot of the sensitivity and specificity of copeptin in predicting mortality in patients with acute coronary syndrome.](pone.0238288.g004){#pone.0238288.g004}
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###### Sensitivity analysis of included studies.

![](pone.0238288.t002){#pone.0238288.t002g}

  Study omitted           Diagnostic odds ratios   95% confidence interval
  ----------------------- ------------------------ -------------------------
  Afzali, et al. 2013     4.76                     2.84--7.97
  Bahrmann, et al. 2013   5.39                     2.95--9.85
  Morawiec, et al. 2018   4.93                     2.81--8.66
  Narayan, et al. 2011    3.57                     1.88--6.77
  Sanchez, et al. 2014    4.89                     2.78--8.61
  Vafaie, et al. 2016     4.99                     2.95--8.46

Between-study heterogeneity {#sec013}
---------------------------

Significant between-study heterogeneity was identified in both sensitivity (*P* = 0.01; *I*^2^ = 69.76%) and specificity (*P*\<0.001; *I*^2^ = 97.32%) among the six included studies. Meta-regression was performed to examine the sources of potential heterogeneity of sensitivity and specificity ([Table 3](#pone.0238288.t003){ref-type="table"}). In the meta-regression, the following covariates were included: study design (prospective cohort study or RCT), number of study centers (multicenter or single-center), sample size (\<500 or ≥500), average age (\<70 years or ≥70 years), duration of follow-up (\<180 days or ≥180 days), study outcome (all-cause mortality or cardiovascular mortality) and cut-off value of copeptin (pre-specified or not pre-specified). The results showed that number of study centers was significantly associated with the heterogeneity of sensitivity (*P* = 0.03). Studies conducted in multiple centers (0.54, 95%: 0.23--0.85) had lower pooled sensitivity compared with studies with single center (0.85, 95%: 0.75--0.94). The study design (*P* = 0.03) and duration of follow-up (*P*\<0.001) were significantly associated with the heterogeneity of specificity. The pooled specificity in clinical trial (0.78, 95%: 0.62--0.94) was much higher than that in prospective cohort studies (0.55, 95%: 0.45--0.66), and the pooled specificity obtained from studies with ≥180 days follow-up (0.75, 95%: 0.64--0.85) was much higher than that obtained from studies with \<180 days follow-up (0.51, 95%: 0.41--0.61). No significant heterogeneity of sensitivity and specificity was identified across studies categorized by sample size, average age, study outcome and pre-specified cut-off value of copeptin.

10.1371/journal.pone.0238288.t003

###### Meta-regression analysis to examine the sources of potential heterogeneity of sensitivity and specificity.

![](pone.0238288.t003){#pone.0238288.t003g}

  Parameter                     Categories                 No. of studies       Sensitivity (95% CI)   *P* value           Specificity (95% CI)   *P* value
  ----------------------------- -------------------------- -------------------- ---------------------- ------------------- ---------------------- -----------
  Study design                  Prospective cohort study   5                    0.82 (0.71--0.93)      0.05                0.55 (0.45--0.66)      0.03
  Randomized control trial      1                          0.33 (-0.26--0.93)                          0.78 (0.62--0.94)                          
  No. of study center           Multicenter                2                    0.54 (0.23--0.85)      0.03                0.75 (0.64--0.85)      0.35
  Single-center                 4                          0.85 (0.75--0.94)                           0.51 (0.41--0.61)                          
  Sample size                   \<500                      4                    0.74 (0.54--0.95)      0.60                0.62 (0.47--0.76)      0.97
  ≥500                          2                          0.84 (0.60--1.00)                           0.56 (0.34--0.77)                          
  Average age, years            \<70                       3                    0.73 (0.45--1.00)      0.70                0.64 (0.48--0.80)      0.33
  ≥70                           3                          0.81 (0.65--0.98)                           0.55 (0.39--0.72)                          
  Duration of follow-up, days   \<180                      4                    0.85 (0.75--0.94)      0.13                0.51 (0.41--0.61)      \<0.001
  ≥180                          2                          0.54 (0.23--0.85)                           0.75 (0.64--0.85)                          
  Study outcome                 All-cause mortality        4                    0.79 (0.61--0.98)      0.80                0.62 (0.48--0.76)      0.91
  Cardiovascular mortality      2                          0.74 (0.45--1.00)                           0.55 (0.34--0.76)                          
  Cut-off value of copeptin     Pre-specified              5                    0.72 (0.54--0.90)      0.28                0.61 (0.48--0.74)      0.79
  Not pre-specified             1                          0.88 (0.70--1.00)                           0.53 (0.23--0.83)                          

CI: confidence interval.

Publication bias {#sec014}
----------------

The Deek's funnel plot asymmetry test was not statistically significant (*P* = 0.44), which suggested that there is no evident indication of publication bias in the included studies ([Fig 5](#pone.0238288.g005){ref-type="fig"}).

![Funnel plot for detecting publication bias.](pone.0238288.g005){#pone.0238288.g005}

Discussion {#sec015}
==========

To our knowledge, this is the first meta-analysis to evaluate the prognostic value of copeptin in patients with ACS. Our meta-analysis including 2269 patients from six studies showed that elevated copeptin was associated with the higher risk of mortality in patients with ACS. The pooled sensitivity and specificity was 0.77 (95% CI: 0.59--0.89) and 0.60 (95% CI: 0.47--0.71), respectively. The AUC of copeptin was 0.73 (95% CI: 0.69--0.77), indicating that copeptin has acceptable performance for predicting mortality in patients with ACS.

Similar to present study, previous studies showed copeptin had prognostic value in patients with heart failure or acute ischemic stroke. Zhong et al. \[[@pone.0238288.ref022]\] conducted a meta-analysis and reported that elevated copeptin level was associated with an increased risk of all-cause mortality in patients with heart failure (relative risk = 2.64, 95% CI: 2.09--3.32), and the performance for predicting mortality in patients with heart failure was acceptable (AUC: 0.70, 95% CI: 0.66--0.74). In another meta-analysis based on data from 1976 patients in six studies, it indicated that elevation in plasma copeptin level carried a higher risk of all-cause mortality in patients with acute ischemic stroke (odds ratio = 4.16, 95% CI: 2.77--6.25) \[[@pone.0238288.ref023]\].

At the current state of knowledge, copeptin could be a potential prognostic marker for ACS due to its acceptable predictive performance. However, there are still several weaknesses for copeptin as prognostic marker for ACS. First, the relationship of copeptin with the risk of mortality in patients with ACS may be influenced by concomitant diseases, such as stroke, renal failure or sepsis, which will affect its application in clinical practice \[[@pone.0238288.ref009], [@pone.0238288.ref024]\]. Second, current evidences don't support that copeptin is a superior predictor of mortality in patients with ACS compared with cardiac troponin T (cTnT) and NT-proBNP, which are well-established biomarkers for diagnosis and prognosis of ACS \[[@pone.0238288.ref025], [@pone.0238288.ref026]\]. Bahrmann et al. found that high-sensitivity cTnT ≥ 0.014 μg/L alone was significantly associated with cardiovascular mortality, while the net reclassification improvement for cardiovascular mortality was not significant (*P* = 0.809) when copeptin ≥ 14 pmol/L was added \[[@pone.0238288.ref014]\]. Another study using data from the MERLIN-TIMI 36 Trial reported that copeptin significantly improved the prognostic value when added to traditional clinical factors (net reclassification index = 0.25, *P*\<0.001), but copeptin and BNP showed similar discrimination capability (c-statistic: 0.69 for copeptin and 0.69 for BNP) \[[@pone.0238288.ref012]\]. Similar results were also reported in another hospital-based prospective cohort study \[[@pone.0238288.ref027]\]. Given that several biomarkers reflect different pathophysiological pathways of response post-MI, we speculated an additive predictive value for combining biomarkers including those of myonecrosis, myocardial strain or stress, and vascular inflammation in CAD prognosis. Previous studies used the multimarker strategy to investigate the risk prediction tool for prognosis of ACS \[[@pone.0238288.ref019], [@pone.0238288.ref028], [@pone.0238288.ref029]\], but the prognostic value of copeptin added to other biomarkers in patients with ACS has not been reported.

There are some potential limitations in this study. First, the number of included studies is relatively small. The Deek's funnel plot asymmetry test was not statistically significant, but publication bias may still exist. Second, the cut-off value of copeptin varied across different studies, and we could not determine the optimized cut-off value due to the lack of raw data. It's worthy to explore the optimized cut-off value of copeptin in future studies. Third, most of included studies were conducted in patients with suspected ACS, as a result, we cannot further evaluate the predictive value of copeptin in patients with non-ST-elevation myocardial infarction and ST-elevation myocardial infarction, respectively in meta-regression analysis.

In conclusion, our study shows that copeptin has prognostic value for mortality in patients with ACS. Future studies based on multimarker strategy are needed to evaluate the prognostic value of copeptin in conjunction with other well-established biomarkers for risk stratification in patients with ACS.
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======================

###### PRISMA 2019 checklist.

(PDF)

###### 

Click here for additional data file.

10.1371/journal.pone.0238288.r001

Decision Letter 0

Lionetti

Vincenzo

Academic Editor

© 2020 Vincenzo Lionetti

2020

Vincenzo Lionetti

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

19 Jun 2020

PONE-D-20-14294

Prognostic value of copeptin in patients with acute coronary syndrome: a systematic review and meta-analysis

PLOS ONE

Dear Dr. Lu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

All issues raised by reviewers are required. Moreover, the authors should add a paragraph describing the limitations of their analysis. Finally, they should better highlight strengths and weaknesses of copeptin as prognostic marker at this stage of knowledge.

Please submit your revised manuscript by Aug 03 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Vincenzo Lionetti, M.D., PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In your Results section, please show the results of the publication bias assessment, including a figure showing the funnel plot.

3\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

4\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: [http://journals.plos.org/plosone/s/supporting-information](about:blank).

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Manuscript Number: PONE-D-20-14294

Jiapeng Lu et co-authors in the paper submitted to PLOSONE (Prognostic value of copeptin in patients with acute coronary syndrome: a systematic review and meta-analysis) evaluated the value of copeptin in predicting mortality in patients with acute coronary syndrome

The manuscript is very interesting and a good review of the literature has been carried out.

Reviewer \#2: Interesting and well conducted meta analysis.

Asbtract; it should be added if we are dealing with in hospital or long term mortality

Abstract authors speak about promising results. An AUC of 0.73 for an exam which is not of routine and has come costs is hard to be defined promising.

Methods/Results: it is not clear if authors used fixed or random effect

Methods/results: meta-regression for age and kind of ACS (stemi vsnstemi) should be performed

Discusson; reduced accuracy of risk scores have been described. this should be commented on (PMID: 32438488)

Reviewer \#3: This is a meta-analysis of six studies investigating the prognostic role of copeptin in patients with ACS. All studies included demonstrated that copeptin could significantly discriminate between patients who died and those who did not die during follow-up. Being this a study-level meta-analysis, it adds very little to the available literature.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Fabrizio D\'Ascenzo

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0238288.r002

Author response to Decision Letter 0

7 Jul 2020

EDITOR\'S COMMENTS:

1\. All issues raised by reviewers are required. Moreover, the authors should add a paragraph describing the limitations of their analysis. Finally, they should better highlight strengths and weaknesses of copeptin as prognostic marker at this stage of knowledge.

Response: We had revised the manuscript according to reviewers' comments and provided responses to each comment. We had a paragraph to describe the potential limitations of our study on page 10, lines 235-243 as follows:

There are some potential limitations in this study. First, the number of included studies is relatively small. The Deek's funnel plot asymmetry test was not statistically significant, but publication bias may still exist. Second, the cut-off value of copeptin varied across different studies, and we could not determine the optimized cut-off value due to the lack of raw data. It's worthy to explore the optimized cut-off value of copeptin in future studies. Third, most of included studies were conducted in patients with suspected ACS, as a result, we cannot further evaluate the predictive value of copeptin in patients with non-ST-elevation myocardial infarction and ST-elevation myocardial infarction, respectively in meta-regression analysis.

According to this comment, we had highlighted strengths and weaknesses of copeptin as prognostic marker based on the discussions in previous version of manuscript on page 10, lines 211-234 as follows:
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According to this comment, we have added a funnel plot for detecting publication bias as Fig 5.

4\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>.

Response: The corresponding author's ORCID is 0000-0001-9179-4587. We have added it in the Editorial Manager system.

5\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Response: No supporting information files was provided in our study.

REVIEWERS\' COMMENTS:

Reviewer \#1:

1\. Manuscript Number: PONE-D-20-14294. Jiapeng Lu et co-authors in the paper submitted to PLOSONE (Prognostic value of copeptin in patients with acute coronary syndrome: a systematic review and meta-analysis) evaluated the value of copeptin in predicting mortality in patients with acute coronary syndrome. The manuscript is very interesting and a good review of the literature has been carried out.

Response: Thank you for your comments.

Reviewer \#2:

1\. Interesting and well conducted meta analysis. Asbtract; it should be added if we are dealing with in hospital or long term mortality

Response: Thank you for your comments. according to this comment, we updated the descriptions in the Abstract on page 1, lines 18-20 as follows:

Background: The aim of this study was to evaluate the value of copeptin in predicting mortality including both short-term and long-term mortality in patients with acute coronary syndrome (ACS).

2\. Abstract authors speak about promising results. An AUC of 0.73 for an exam which is not of routine and has come costs is hard to be defined promising.

Response: We have updated the word we used in the Abstract on page 1, lines 36-37 as follows:

Copeptin has acceptable prognostic value for mortality in patients with ACS.

3\. Methods/Results: it is not clear if authors used fixed or random effect

Response: We mentioned that we used a random-effects model to calculate pooled sensitivity and specificity in Methods section on page 5, lines 97 as follows:

We calculated pooled sensitivity and specificity using a random-effects model.

4\. Methods/results: meta-regression for age and kind of ACS (stemi vs nstemi) should be performed

Response: According to this comment, we have added the results of meta-regression for age in Table 3 as follows:

Table 3. Meta-regression analysis to examine the sources of potential heterogeneity of sensitivity and specificity

Parameter Categories No. of studies Sensitivity (95% CI) P value Specificity (95% CI) P value

Study design Prospective cohort study 5 0.82 (0.71 - 0.93) 0.05 0.55 (0.45 - 0.66) 0.03

Randomized control trial 1 0.33 (-0.26 - 0.93) 0.78 (0.62 - 0.94)

No. of study center Multicenter 2 0.54 (0.23 - 0.85) 0.03 0.75 (0.64 - 0.85) 0.35

Single-center 4 0.85 (0.75 - 0.94) 0.51 (0.41 - 0.61)

Sample size \<500 4 0.74 (0.54 - 0.95) 0.60 0.62 (0.47 - 0.76) 0.97

≥500 2 0.84 (0.60 - 1.00) 0.56 (0.34 - 0.77)

Average age, years \<70 3 0.73 (0.45 -- 1.00) 0.70 0.64 (0.48 - 0.80) 0.33

≥70 3 0.81 (0.65 -- 0.98) 0.55 (0.39 - 0.72)

Duration of follow-up, days \<180 4 0.85 (0.75 - 0.94) 0.13 0.51 (0.41 - 0.61) \<0.001

≥180 2 0.54 (0.23 - 0.85) 0.75 (0.64 - 0.85)

Study outcome All-cause mortality 4 0.79 (0.61 - 0.98) 0.80 0.62 (0.48 - 0.76) 0.91

Cardiovascular mortality 2 0.74 (0.45 - 1.00) 0.55 (0.34 - 0.76)

Cut-off value of copeptin Pre-specified 5 0.72 (0.54 - 0.90) 0.28 0.61 (0.48 - 0.74) 0.79

Not pre-specified 1 0.88 (0.70 - 1.00) 0.53 (0.23 - 0.83)

CI: confidence interval.

We also updated the results on page 8, lines 179-181 as follows:

No significant heterogeneity of sensitivity and specificity was identified across studies categorized by sample size, average age, study outcome and cut-off value of copeptin.

Most of included studies recruited patients with suspected ACS including both STEMI and NSTEMI. But original data used to calculate sensitivity and specificity were not available for STEMI and NSTEMI, respectively. Thus, we cannot conduct meta-regression analysis for the kind of ACS.

5\. Discusson; reduced accuracy of risk scores have been described. this should be commented on (PMID: 32438488)

Response: We didn't mention about the reduced accuracy of risk scores in the Discussion section. And the publication (PMID: 32438488) you mentioned is about the accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations. We realized that this study is not relevant to the research top in our study. Therefore, we didn't make any change based on this comment.

Reviewer \#3:

1\. This is a meta-analysis of six studies investigating the prognostic role of copeptin in patients with ACS. All studies included demonstrated that copeptin could significantly discriminate between patients who died and those who did not die during follow-up. Being this a study-level meta-analysis, it adds very little to the available literature.

Response: Thank you for your comments. Among the six included studies, there is one study reporting no significant association of copeptin with the risk of mortality among patients with ACS\[11\]. In addition, our study was not only to evaluate the association between copeptin and mortality, but also to quantify the value of copeptin in predicting mortality in patients with ACS.
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